ER+ breast cancers initially respond well to endocrine therapy such as estrogen receptor targeting drug tamoxifen [5]; however, one third of metastatic ER+ breast cancer cases gradually lose ER expression and acquire resistance to these agents [6]. Here, ESR1 is linked to breast cancer.